Saba Capital’s Steady Accumulation at Ellsworth Growth Signals Confidence Amid Recovery Challenges

Saba Capital’s Steady Accumulation at Ellsworth Growth and Income

Saba Capital Management, L.P. has been methodically building a sizable stake in Ellsworth Growth and Income (NYSE AM: ELI) over the past six months. After a series of sizable purchases in late August and early September 2026—ranging from 1,200 shares to 6,800 shares—Saba’s holdings climbed to more than 1.63 million shares, roughly 13 % of the fund’s outstanding shares. The latest transaction on October 7th added 17,548 shares at $11.97, bringing the total to 1,646,010 shares and a post‑transaction average cost of approximately $12.10 per share. The current market price of $19.02 represents a near‑$7 premium over the cost basis, underscoring the confidence the firm places in ELI’s turnaround trajectory.

Implications for Investors and the Company’s Outlook

The accumulation coincides with a period of significant operational distress for ELI. The 2025 year‑end results highlighted inventory losses, a fire incident, and asset impairments that eroded profitability and raised a red flag on the fund’s going‑concern status. Management’s response has involved restructuring, safety upgrades, and a comprehensive recovery plan. Saba’s buying spree suggests that the firm believes the fund’s corrective actions will restore value and that the current price is undervalued relative to the projected recovery. For investors, the move is a double‑edged sword: on one hand, it signals confidence in ELI’s management; on the other, it increases concentration risk for shareholders who may have to follow suit or hedge against a potential rebound.

Profile of Saba Capital Management, L.P.

Saba Capital is a quantitative investment firm that typically engages in systematic, long‑term equity investments. Historically, the firm has displayed a preference for accumulation rather than speculation. Its transactions in 2026 reveal a pattern of buying at price points near $12–$12.5, often after a brief period of sell activity in February when market conditions were less favorable. The firm’s trading cadence—clusters of purchases followed by consolidation—indicates a disciplined approach aimed at building a significant position while maintaining liquidity. The recent October purchase aligns with this pattern, reinforcing the narrative that Saba views ELI as a high‑potential, value‑trading opportunity.

What This Means for the Future

If Saba’s bet pays off, the fund could experience a sharp upside, benefiting shareholders who hold the stock. The firm’s continued presence may also provide a stabilizing effect, reassuring other investors that institutional confidence remains strong. Conversely, if ELI’s recovery stalls or the market reacts negatively to the ongoing operational challenges, Saba could face losses on its sizable holding. The company’s management will need to accelerate its turnaround plan and transparently communicate progress to mitigate downside risk. For investors, monitoring Saba’s subsequent filings will provide key signals on whether the fund’s strategy is proving effective, offering an early indicator of ELI’s broader market sentiment.

Bottom Line

Saba Capital’s recent buying spree at Ellsworth Growth and Income reflects a calculated, long‑term investment thesis amid a backdrop of operational recovery. The firm’s disciplined accumulation strategy and the premium it pays above cost basis suggest confidence that ELI’s corrective measures will generate substantial shareholder value. Investors should weigh the potential upside against concentration risk and keep an eye on the fund’s progress reports, as Saba’s actions will continue to influence market perception and price momentum.